Hisako Matsumoto

Chief Professor

Kindai University
Country flagJapan
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Sarcoidosis is a multisystem granulomatous disease that rarely involves the bone marrow and is particularly uncommon during chemotherapy. A 56‐year‐old Japanese woman with stage IIIc fallopian tube carcinoma developed persistent high‐grade fever and new bilateral pulmonary nodules two weeks after paclitaxel–carboplatin and bevacizumab therapy, which was complicated by neutropenia. Initial evaluations, including imaging, microbiological studies and bronchoscopy, excluded infection and malignancy recurrence. Histological analysis of bone marrow and transbronchial lung biopsy specimens demonstrated non‐caseating granulomas, confirming sarcoidosis despite normal serum angiotensin‐converting enzyme levels and absence of lymphadenopathy. Her fever and pulmonary nodules resolved spontaneously without corticosteroid therapy. This case underscores the importance of considering sarcoidosis in the differential diagnosis of fever and new pulmonary lesions in patients undergoing chemotherapy. Early histopathological confirmation is essential to avoid misdiagnosis and guide appropriate management.

Year:

2025

Background The real-world efficacy of the P2X3 antagonist gefapixant, a new class of antitussive for refractory chronic cough, is not yet fully understood. This study aimed to evaluate the real-world usage and response to gefapixant in patients with refractory chronic cough. Methods This multicentre retrospective study involved patients with refractory chronic cough who visited cough clinics and were prescribed gefapixant. Data collected included baseline demographics, cough characteristics, response to gefapixant, degree of taste disturbance (both assessed by cough specialists), and the course of cough after discontinuation, if applicable. Results 272 cases were analysed. The population was predominantly middle-aged females, with most patients having asthmatic cough as a comorbidity, dry cough, and predominantly daytime cough. Half of the patients reported a response rate of ≥5 on a 0–10 scale, with 25% reporting a response rate of ≥8. Among responders (response rate ≥5), improvement was largely seen within 2 weeks. The median treatment duration with gefapixant was 32 days (interquartile range 14–175 days), with longer treatment periods observed in responders. Responders typically had more severe pre-treatment cough, dry cough, asthmatic cough as a comorbidity and specific laryngeal sensations. In patients who discontinued gefapixant, sustained improvement was observed in responders. Taste disturbance was not associated with response to gefapixant and was less frequent in patients with cough triggers such as smoke, dry air, or scents, than in those without these triggers. Conclusions Gefapixant demonstrated a rapid and effective antitussive effect in this multicentre, real-world study.

Year:

2025

Background Dipeptidyl peptidase 1 (DPP1) exacerbates airway neutrophilic inflammation in bronchiectasis, which is characterised by airway dysfunction and dilation and chronic bacterial infection. However, little is known about the pathogenetic roles of DPP1 in obstructive airway diseases, including COPD, asthma and asthma–COPD overlap (ACO). Here, we tested the hypothesis that airway DPP1 could enhance neutrophilic inflammation and affect mucus plugging, airway dilation and the airway microbiome in patients with these diseases. Methods Sputum DPP1, cell differential count and microbiome were cross-sectionally evaluated in patients with COPD, asthma with airflow limitation and ACO. Sputum high mobility group box 1 (HMGB1) was measured to estimate airway epithelial damage. Chest computed tomography was also performed to visually assess mucus plugs and airway dilation with the Reiff score and quantify the total airway count and wall area percentage. Results 68 patients were classified into high-DPP1/high-neutrophil (n=17), low-DPP1/high-neutrophil (n=37) and low-neutrophil (n=14) groups based on sputum DPP1 levels and neutrophil percentages. The rate of mucus plugging and the relative abundance of the phylum Firmicutes were significantly lower and the level of sputum HMGB1 was significantly greater in the high-DPP1/high-neutrophil group than in the low-DPP1/high-neutrophil group. Moreover, airway dilation without mucus plugging was observed only in the high-DPP1/high-neutrophil group (prevalence 29%). Conclusions High sputum DPP1 levels may reduce colonisation by the phylum Firmicutes and mucus plugging, but increase airway epithelial damage, which could induce airway dilation without mucus plugging in patients with obstructive airway disease with neutrophilic inflammation.

Year:

2024

Background Asthma is a heterogeneous disease with variable response to treatment. Genetic backgrounds are involved in the severity of type 2 asthma, but their effects on responses to biologics remain unknown. This study aimed to clarify the role of genetic factors in response to biologics in patients with severe asthma. Methods Adults with severe asthma receiving biologics were enrolled in this multicentre, observational, real-world study. The responses to biologics were evaluated using Physicians’ Global Evaluation of Treatment Effectiveness (GETE). Optimal biologic for each patient was also determined based on the best GETE score for the biologic used or currently used biologic. Three single nucleotide polymorphisms ( IL1RL1 , rs1420101; IL4RA , rs8832; and TSLP rs1837253) were examined. Results Among the 113 patients analysed, 53 (46.9%) had an excellent GETE score for at least one biologic. These patients with an excellent GETE score for at least one biologic, particularly for benralizumab, had the risk genotype of rs1420101 more frequently than the remaining patients, independent of the clinical demographics. Regarding the optimal biologic for each patient, anti-IL-5 drugs were optimal for patients with the rs1420101 TT or rs8832 GG genotype. Furthermore, dupilumab was similarly effective, regardless of the risk genotypes examined in this study. Conclusion IL1RL1 rs1420101 TT genotype and/or IL4RA rs8832 GG genotype may predict an excellent or optimal response to biologic therapy in each patient, particularly to anti-interleukin-5 targeted therapy. The elucidation of genetic predisposition may improve the management of severe asthma in the era of biologics.

Year:

2024

Objective Inspiratory muscle training (IMT) is used to improve inspiratory muscle strength in patients with COPD. However, the effect of IMT on diaphragmatic function has not yet been thoroughly evaluated. This study aimed to evaluate the effect of IMT on maximum diaphragmatic excursion (DE max ) using ultrasonography in patients with COPD. Methods This was a single-centre, randomised, prospective, parallel-group, unblinded controlled trial involving 38 participants with stable COPD. Participants underwent a standardised 12-week pulmonary rehabilitation (PR) programme followed by a 12-week IMT programme, consisting of home-based IMT and low-frequency outpatient PR sessions supervised by physiotherapists (once every 2 weeks), versus low-frequency outpatient PR alone as a control. The DE max and exercise tolerance were measured. Results Out of the 38 patients initially enrolled in the PR programme, 33 successfully completed it and were subsequently randomised to the IMT programme. Finally, 15 (94%) and 14 (88%) patients from the IMT and control groups, respectively, completed the study. Following the IMT programme, DE max increased in the IMT group (mean± sd 50.1±7.6 mm to 60.6±8.0 mm, p<0.001), but not in the control group (47.4±7.9 mm to 46.9±8.3 mm, p=0.10). Changes in DE max and exercise tolerance (peak oxygen uptake) were greater in the IMT group than in the control group (both p<0.01). Conclusions IMT following the PR programme improved DE max and exercise tolerance. Therefore, DE max may be an important outcome of IMT.

Year:

2024

Collaborators (5)

Shintarou Kudo

Morinomiya University of Medical Sciences

JAPAN
View details

Tatsuya Nagano

Kobe University Graduate School of Medicine

JAPAN
View details

Tamotsu Ishizuka

Professor

University of Fukui

JAPAN
View details

NAOYA TANABE

Kyoto University Hospital

JAPAN
View details

Toyohiro Hirai

Kyoto University

JAPAN
View details